Abstract 350P
Background
Currently, various chemotherapy regimens have been reported for the efficacy of unresectable squamous cell carcinoma (cSCC). However, there is no clear consensus. Here, we report the treatment results of unresectable cSCC in which concurrent chemoradiotherapy (CCRT) combining low-dose cisplatin and 5-fluorouracil (low-dose FP therapy) was performed in our department.
Methods
A two-year retrospective study was conducted for 23 patients who had been received CCRT with low-dose FP therapy for unresectable cSCC. The patient age ranged from 44 to 79 years (mean age, 71 years), and gender was 17 men and 6 women. The primary lesions of unresectable cSCC were present in 7 cases in the head and neck, in 1 case in the upper limbs, in 5 cases in the lower limbs, and in 10 cases in the perineal region. Radiotherapy (RT) of CCRT had irradiated the primary lesion and regional lymph nodes. And for chemotherapy of CCRT, low-dose FP therapy was used.
Results
When 23 patients were classified by TNM staging (UICC 8th), stage 3 of unresectable cSCC was 5 patients (21.7%) and stage 4 was 18 patients (78.3%). 6 cases who those with stage 4 were dead (26.1%), while there were no dead cases who those with stage 3. Overall response rate (ORR) was 81 %, and median progression-free survival (PFS) was 392 days. For stage 4 of unresectable cSCC, one-year overall survival (OS) was 78 %, two-year OS was 56.7%, median survival time (MST) was 560 days.
Conclusions
CCRT with low-dose FP therapy is an effective treatment for unresectable cSCC. However, tumors of the primary lesion and / or regional lymph nodes may remain after CCRT. In such cases, chemotherapy (i.e., maintenance therapy [MT]) should be continued after CCRT. In our department, most cases of unresectable cSCC receive MT after CCRT. Therefore, in the first treatment of unresectable cSCC, it is important how to make the tumor smaller. In this study, our cases had optimal results of ORR, median PFS, OS, and MST. According to these facts and results, we considered CCRT with low-dose FP therapy suppressed cSCC and is an effective treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
Presenter: Yusuke Sasaki
Session: Poster display session
Resources:
Abstract
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract